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Thrombomodulin (TM) is an endothelial receptor that exhibits anticoagulant, antifibrinolytic and anti-inflammatory activity by
inhibiting thrombin and cellular adhesion. In this study, the expression and significance of TM was examined in primary colorectal
cancer and its prognostic implications explored. TM immunostaining was performed on formalin-fixed, paraffin-embedded tissue
sections, from primary lesions of 200 patients with colorectal carcinoma. Institutional Ethical approval was granted and clinical data
retrieved from patients’ records. All normal colonic tissue expressed TM on endothelial cells. TM tumour cell expression was
demonstrated in 53 (26.5%) cases and 147 (73.5%) showed no neoplastic cell staining. On univariate and multivariate analysis TM
expression on tumour cells correlated significantly with tumour stage, differentiation, Jass score and 5 year survival. TM expression
decreases as overall stage and tumour size increase (P¼0.03). In all, 91% TM positive tumours were well differentiated and 85% of
TM negative tumours were poorly differentiated (Po0.01). Five year survival rates of patients with positive and negative TM
expression were 71 and 41%, respectively. Survival rate was poorer in those patients who were TM negative compared with those
who were positive (Po0.01). A total of 101 (50.5%) of the cases were node negative. In this group, 5 year survival rates of patients
with positive and negative TM expression were 87.5 and 37.8%, respectively, demonstrating a poorer survival rate for those who are
node negative and TM negative at the time of surgery (Po0.001). This study demonstrates that loss of TM is a key indicator in
tumour biology and prognosis.
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Thrombomodulin (TM) is a membrane-bound glycoprotein
initially identified on vascular endothelium and later on leuco-
cytes, mesothelium, keratinocytes and astrocytes. Expression is
affected by a range of pathophysiological stimuli (Maruyama et al,
1985; Dittman et al, 1989; Ohji et al, 1995; Calnek and Grinnell,
1998; Ishii et al, 2003; Shi et al, 2003) and the effect of a specific
stimulus varies with the cell type involved (Grey et al, 1998).
TM plays a role in three major processes in vivo: coagulation,
inflammation and cell adhesion. It was discovered by its anti-
coagulant activity, to be an essential co-factor for thrombin-
mediated activation of Protein C (Esmon and Owen, 1981, 2004)
and thrombin-activated fibrinolysis inhibitor (TAFI) (de Munk
et al, 1991), both of which demonstrate fibrinolytic activity.
Through these mechanisms, the function of TM as a natural
anticoagulant has been well documented.
The anti-inflammatory role of TM has been clearly demon-
strated in vivo. It reduces restenosis (Waugh et al, 1999), modifies
the inflammatory response (Weiler et al, 2001), prevents leucocyte
infiltration (Ikeguchi et al, 2002), and these effects are mediated by
a range of mechanisms (Weiler et al, 2001; Conway et al, 2002).
The role of TM in malignancy is, in contrast relatively unknown.
TM expression has been immunohistochemically demonstrated in
a wide variety of human tumours, (Tezuka et al, 1995; Hamatake
et al, 1996; Kim et al, 1997; Ordonez, 1997; Tabata et al, 1997;
Wilhelm et al, 1998; Zhang et al, 1998; Ogawa et al, 2000), which
mostly reveal a correlation between reduced TM expression and
shorter survival or increased metastases (Hamatake et al, 1996;
Kim et al, 1997; Tabata et al, 1997; Ogawa et al, 2000).
The exact mechanism(s) by which TM acts within a tumour has
not been clearly outlined. Anticoagulation, adhesion, differentia-
tion and proliferation have all been suggested. What is known
is that malignancy has a profound impact on the haemostatic
system, with increasing recognition of the role in tumour biology
of coagulation factors, anticoagulants, activators and inhibitors
of fibrinolysis (Iqbal, 2000). TM may, therefore, influence tumour
growth and metastasis via its role as a natural anticoagulant.
TM expression is concentrated in regions of cell to cell contact
(Jackson et al, 1995; Tezuka et al, 1995). It has also been demon-
strated to colocalize with actin filaments (Huang et al, 2003)
suggesting an involvement in intercellular communication or
(cell–cell) adhesion. Mirroring other cell-adhesion molecules, TM
expression tends to be lower in metastatic lesions than in matched
primary specimens (Tezuka et al, 1995; Hamatake et al, 1996;
Tabata et al, 1997; Ogawa et al, 2000).
TM is expressed during embryonic development and is
associated with cell differentiation (Imada et al, 1990). In oral
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ssquamous epithelium, TM expression reduces in parallel with the
transition from normal mucosa to dysplasia and overt carcinoma
(Tabata et al, 1995). In tumours, therefore, decreased TM may
induce loss of differentiation and enhance metastatic behaviour.
In vitro work has demonstrated that TM reduces tumour cell
proliferation and invasion (Matsushita et al, 1998; Zhang et al, 1998;
Hosaka et al, 2000; Huang et al, 2003) and TM expressing cells
produce smaller tumours in vivo (Zhang et al, 1998; Huang et al,
2003). There are, therefore, many possible mechanisms by which
increased TM expression could decrease the likelihood of metastasis.
TM is not as prevalent in adenocarcinomas as in squamous
cell carcinomas. In one study, o20% of adenocarcinomas of the
pancreas, breast and lung were found to express TM, with no
expression seen in prostatic or colonic adenocarcinoma. However,
only a small number of specimens were examined (Ordonez, 1997).
In a small study of 21 patients with colonic adenocarcinoma,
expression on the vasculature increased as tumours progressed
along the dysplasia-carcinoma sequence (Takebayashi et al, 1995).
Expression of TM in colonic adenocarcinoma has not previously
been examined in a large cohort. The aim of this study was to
examine TM expression in tissue extracts of patients with primary
colorectal cancer and determine if this correlates with tumour
stage and prognosis.
MATERIALS AND METHODS
Specimens from 200 consecutive patients who underwent surgery
for primary adenocarcinoma of the colon between 1994 and 1999
were included in this study. The median (range) age of patients
was 69 (34–90) years (male 66.5%, female 33.5%). Patients with
radiological evidence of metastasis, or who had preoperative
chemo or radiotherapy, were excluded. Ethics approval was
granted and relevant information was collected from clinical
records, primary care physicians and, where necessary, patient
contact. Location of tumours, overall stage and tumour stage
classified by the TNM classification are outlined in Tables 1, 2
and 3, respectively. Evaluation of malignancy was based on
original haematoxylin and eosin stained sections at the time of
diagnosis. TM expression in the primary tumours was examined
immunohistochemically. Formalin-fixed paraffin-embedded colo-
rectal tumours were retrieved from the archives. Sections were
cut at 4mm, deparaffinised and rehydrated in descending grades
of alcohol (100–70%). Following heat-mediated antigen retrieval,
slides were run on an automated immuno-stainer (Nexes from
Ventana, AZ, USA). Primary antibody was a mouse monoclonal
antibody raised against the EGF domains 4–6 of TM (Dako
Table 1 Distribution of primary tumours within the colon
Site of tumour Number of tumours
Recto-sigmoid 82
Left colon 46
Transverse colon 8
Right colon 31
Caecum 33
Table 2 Comparison of overall colonic tumour stage as defined by the
American joint committee on colorectal cancer (AJCC), with positive and
negative TM expression groups
Stage
No.
patients
TM-positive
(%) (n¼56)
TM-negative
(%) (n¼144) P-Value
I 17 9 (52.9%) 8 (47.1%) *P¼0.08
II 84 23 (27.4%) 61 (72.6%)
III 99 24 (24.2%) 75 (75.8%)
*Overall analysis of variance. *Comparison of stage I vs II-P¼0.06, I vs III-
P¼0.025, II vs III-P¼0.63.
Table 3 Correlation of tumour stage (AJCC) with TM positive and
negative groups
Tumour
grade
No. of
patients
TM-positive (%)
(n¼56)
TM-negative
(%) (n¼144) P-Value
T1 2 1 (50%) 1 (50%) *P¼0.03
T2 28 14 (50%) 14 (50%)
T3 147 35 (23.8%) 112 (76.2%)
T4 23 6 (26.1%) 17 (73.9%)
*Overall analysis of variance.
Figure 1 This slide demonstrates a TM negative tumour with internal
positive control staining of the vessel endothelium. The slide is magnified to
demonstrate this clearly.
Figure 2 This slide demonstrates a section of colorectal tumour with
þ1 TM staining, internal positive control is also evident in this image.
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sGlostrup, Denmark; 1:50 dilution). The immunostaining was
developed using diaminobenzidine as a chromagen. Vascular
endothelium acted as a positive internal control (Figures 1 and 2),
the primary antibody was omitted for negative controls and this
was confirmed using an isotype-matched primary monoclonal
antibody (DAKO Cytomation M0792 at 1:2000 dilution) (Figure 3).
Results were quantitatively evaluated by two blinded pathologists.
Slides were graded according to intensity of staining on tumour
cells and were classified as 0, completely negative; þ1, under
10% of neoplastic cells stained; þ2 10–50% of neoplastic cells
stained and þ3 over 50% of neoplastic cells stained. No slides
demonstrated þ3 staining and no statistical difference was noted
between þ1 and þ2 staining when compared with tumour grade,
stage and overall survival. Therefore, analysis was performed using
two groups, TM positive and TM negative.
Statistical analysis was performed using Stats Direct (version
2.3.8. Cheshire, UK). Expression rates of TM were analysed using
the Mann–Whitney U-test. Clinical outcome data was evaluated
using the w
2 and Kaplan–Meier method. A probability of Po0.05
was considered statistically significant.
RESULTS
Endothelial cell TM expression was identical in normal and
neoplastic colonic tissue, which acted as a positive internal
control. Interestingly, however, epithelial TM expression revealed
a marked difference with 7.8 and 26.5% TM positivity in normal
and neoplastic colonic tissue, respectively. TM tumour cell
expression was demonstrated on 53 (26.5%) tumours and 147
(73.5%) showed no neoplastic cell staining. Tables 2 and 3
compare TNM staging with positive and negative TM expres-
sion groups. This significantly demonstrates that negative TM
expression correlates with advanced stage and tumour grade.
On univariate and multivariate analysis tumour differentiation
correlated with TM expression, with increasing expression seen
in well-differentiated tumours compared with moderate and
poorly differentiated (Po0.001) (Figure 4). There was no corre-
lation found between site of tumour and extent of TM tumour
staining. A comparison was made between TM tumour cell
expression and Jass Score, expression decreasing exponentially
as the Jass Score increased (Figure 5). This correlation with Jass
score was not identified when comparing TM expression on
the vasculature or inflammatory cells.
A survival analysis was carried out using the Kaplan–Meier
method. Clinical data was complete in 100% of patients. Of the 200
patients included in this study 35 (17.5%) experienced noncancer-
related deaths and were considered censored in the Kaplan–Meier
survival analysis. Comparisons were then made with survival and
TM expression groups in the primary tumour. The 5 year survival
rates of patients with positive and negative TM expression were
71 and 41%, respectively (Po0.01) (Figure 6).
Figure 3 Isotype-matched primary monoclonal antibody negative
control.
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Figure 4 This figure demonstrates that over 90% of well-differentiated
tumours were TM positive compared with 24 and 14% of moderate and
poorly differentiated. Demonstrating increased TM expression in more
well-differentiated tumours (Mann–Whitney U-test).
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Figure 5 This figure demonstrates that as tumour Jass Score increases
the amount of TM positive tumours exponentially decreases.
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Figure 6 Comparison of the survival between groups which are TM
positive and TM negative. The patients who were TM negative showed
a significantly poorer survival than those who were TM positive.
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sWe analysed TM expression in the 101 (50.5%) patients
who were node negative. The 5 year survival rates of patients
with positive and negative TM expression were 87.5 and 37.8%,
respectively (Po0.01) (Figure 7). Comparatively, we analysed
those 99 (49.1%) patients, who were node positive, with 23.3 and
76.7% TM positive and TM negative, respectively. Similar to those
who were node negative, 5 year survival was significantly better
in those who were TM positive (Figure 8).
All ulcerated tumours expressed membranous TM on inflam-
matory cells within the ulcer, representing 164 (82%) of all
tumours (Figure 9). TM tumour expression was similar in
ulcerated and nonulcerated tumours, with 28 vs 26% TM positivity
in ulcerated and nonulcerated tumours, respectively. Tumour
staining was evenly distributed throughout ulcerated tumours and
no localization of tumour cell TM expression was noted within or
surrounding ulcerated areas. On further analysis patients with
ulcerated tumours had poorer 5 year survival rates compared with
those without ulceration, 47.1 and 61.1%, respectively (Po0.01).
Tumours within the ulcerated group, which expressed TM,
demonstrated a similarly improved survival to those in the
nonulcerated group. Poorer overall survival in ulcerated tumours
could not then be correlated with TM expression.
DISCUSSION
TM is known to be produced predominately by vascular endothelial
cells (Esmon, 1989; Lindahl et al, 1993), effecting local as well as
systemic action, suggested by its presence in the plasma of healthy
individuals (Lindahl et al, 1993). It has been widely investigated as
a marker of inflammatory and vascular disease with high plasma
and endothelial levels mirroring severity (Weiler and Isermann,
2003). More recently, TM expression was demonstrated constitu-
tively by some epithelial carcinomas, with decreased expression
associated with metastases and high recurrence rates (Iino et al,
2004). It was the aim of this study to investigate the expression of
TM in a large cohort of primary colorectal adenocarcinomas and to
correlate this expression with clinical data.
Tumour cell staining was inversely and significantly correlated
with overall stage (Table 2), T stage (Table 3), differentiation
(Figure 4), Jass Score (Figure 5) and 5 year survival (Figure 6),
suggesting that the presence of TM on colorectal tumour cells
inhibits differentiation and may regulate tumour growth and
metastasis. TM expression was associated with improved 5 year
survival in both node negative and node positive patients.
Tumours without TM expression were more likely to be poorly
differentiated and have a worse prognosis (Po0.01).
Ulcerated tumours had similar neoplastic cell TM expres-
sion compared with nonulcerated tumours. However, ulcerated
tumours demonstrated greater TM expression predominantly
on inflammatory cells of the ulcer. Ulcerated tumours were asso-
ciated with poorer survival compared with nonulcerated tumours
(Po0.01), despite no significant difference in TM expression,
tumour grade or TNM stage. Ulcerated tumours are known to have
a worse prognosis compared with nonulcerated tumours, but TM
positivity within the ulcerated group was associated with a better
prognosis. Poorer survival rates of ulcerated tumours are therefore
thought to be independent of TM tumour cell expression.
TM expression on colorectal tumour cells correlated with overall
improved survival in this study. In addition, node negative (Dukes’
B) and node positive (Dukes’ C) tumours independently demon-
strated significantly improved survival rates with TM positive
vs TM negative expression. It would seem, therefore, that similar to
squamous and other epithelial carcinomas, neoplastic TM expres-
sion is protective in primary colorectal adenocarcinomas. How-
ever, unlike squamous cells where TM is expressed under normal
conditions (Mizutani et al, 1996; Yonezawa et al, 1987) only 7.8%
of normal colonic epithelial cells expressed TM. Therefore, while
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Figure 7 Comparison of the survival between TM positive and TM
negative node negative tumours. Patients who are node negative and TM
negative show a significantly poorer 5 year survival compared with those
who are node negative and TM positive.
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Figure 8 Comparison of the survival between TM positive and TM
negative node positive tumours. Patients who are node positive and TM
negative show a significantly poorer 5 year survival compared with those
who are node positive and TM positive.
Figure 9 Ulcerated colorectal lesion demonstrating membranous TM
staining on the inflammatory cells of the ulcer.
Thrombomodulin and colorectal carcinoma
AM Hanly et al
1323
British Journal of Cancer (2006) 94(9), 1320–1325 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
scolonic epithelial cells do not produce TM under normal
conditions, they must be phenotypically capable of doing so in
certain environments.
Future work on the manipulation of TM and understanding
further its role in proliferation, differentiation and adhesion, will
be important in clarifying the function of TM in tumour growth
and metastases. There are already many known inducers of TM
expression (Hanly et al, 2005) and by understanding the role of
TM in adenocarcinomas, these inducers may provide future
potential therapies to modulate tumour behaviour and decrease
metastases.
ACKNOWLEDGEMENTS
We thank Mr Colm Buckley.
REFERENCES
Calnek DS, Grinnell BW (1998) Thrombomodulin-dependent anticoagulant
activity is regulated by vascular endothelial growth factor. Exp Cell Res
238: 294–298
Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese
A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, Herbert JM, Collen D,
Theilmeier G (2002) The lectin-like domain of thrombomodulin confers
protection from neutrophil-mediated tissue damage by suppressing
adhesion molecule expression via nuclear factor kappaB and mitogen-
activated protein kinase pathways. J Exp Med 196: 565–577
de Munk GA, Groeneveld E, Rijken DC (1991) Acceleration of the thrombin
inactivation of single chain urokinase-type plasminogen activator
(pro-urokinase) by thrombomodulin. J Clin Invest 88: 1680–1684
Dittman WA, Kumada T, Majerus PW (1989) Transcription of thrombo-
modulin mRNA in mouse hemangioma cells is increased by cyclo-
heximide and thrombin. Proc Natl Acad Sci USA 86: 7179–7182
Esmon CT (1989) The roles of protein C and thrombomodulin in the
regulation of blood coagulation. J Biol Chem 264: 4743–4746
Esmon CT, Owen WG (1981) Identification of an endothelial cell cofactor
for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA
78: 2249–2252
Esmon CT, Owen WG (2004) The discovery of thrombomodulin. J Thromb
Haemost 2: 209–213
Grey ST, Csizmadia V, Hancock WW (1998) Differential effect of tumor
necrosis factor-alpha on thrombomodulin gene expression by human
monocytoid (THP-1) cell vs endothelial cells. Int J Hematol 67: 53–62
Hamatake M, Ishida T, Mitsudomi T, Akazawa K, Sugimachi K (1996)
Prognostic value and clinicopathological correlation of thrombomodulin
in squamous cell carcinoma of the human lung. Clin Cancer Res 2:
763–766
Hanly AM, Hayanga A, Winter DC, Bouchier-Hayes DJ (2005) Thrombo-
modulin: tumour biology and prognostic implications. Eur J Surg Oncol
31: 217–220
Hosaka Y, Higuchi T, Tsumagari M, Ishii H (2000) Inhibition of invasion
and experimental metastasis of murine melanoma cells by human soluble
thrombomodulin. Cancer Lett 161: 231–240
Huang HC, Shi GY, Jiang SJ, Shi CS, Wu CM, Yang HY, Wu HL (2003)
Thrombomodulin-mediated cell adhesion: involvement of its lectin-like
domain. J Biol Chem 278: 46750–46759
Iino S, Abeyama K, Kawahara K, Yamakuchi M, Hashiguchi T, Matsukita S,
Yonezawa S, Taniguchi S, Nakata M, Takao S, Aikou T, Maruyama I
(2004) The antimetastatic role of thrombomodulin expression in
islet cell-derived tumors and its diagnostic value. Clin Cancer Res 10:
6179–6188
Ikeguchi H, Maruyama S, Morita Y, Fujita Y, Kato T, Natori Y, Akatsu H,
Campbell W, Okada N, Okada H, Yuzawa Y, Matsuo S (2002) Effects of
human soluble thrombomodulin on experimental glomerulonephritis.
Kidney Int 61: 490–501
Imada S, Yamaguchi H, Nagumo M, Katayanagi S, Iwasaki H, Imada M
(1990) Identification of fetomodulin, a surface marker protein of fetal
development, as thrombomodulin by gene cloning and functional assays.
Dev Biol 140: 113–122
Iqbal S (2000) Role of thrombomodulin in cancer biology. Breast 9:
264–266
Ishii H, Tezuka T, Ishikawa H, Takada K, Oida K, Horie S (2003) Oxidized
phospholipids in oxidized low-density lipoprotein down-regulate throm-
bomodulin transcription in vascular endothelial cells through a decrease
in the binding of RARbeta-RXRalpha heterodimers and Sp1 and Sp3 to
their binding sequences in the TM promoter. Blood 101: 4765–4774
Jackson DE, Mitchell CA, Bird P, Salem HH, Hayman JA (1995)
Immunohistochemical localization of thrombomodulin in normal
human skin and skin tumours. J Pathol 175: 421–432
Kim SJ, Shiba E, Ishii H, Inoue T, Taguchi T, Tanji Y, Kimoto Y, Izukura M,
Takai S (1997) Thrombomodulin is a new biological and prognostic
marker for breast cancer: an immunohistochemical study. Anticancer
Res 17: 2319–2323
Lindahl AK, Boffa MC, Abildgaard U (1993) Increased plasma thrombo-
modulin in cancer patients. Thromb Haemost 69: 112–114
Maruyama I, Bell CE, Majerus PW (1985) Thrombomodulin is found on
endothelium of arteries, veins, capillaries, and lymphatics, and on
syncytiotrophoblast of human placenta. J Cell Biol 101: 363–371
Matsushita Y, Yoshiie K, Imamura Y, Ogawa H, Imamura H, Takao S,
Yonezawa S, Aikou T, Maruyama I, Sato E (1998) A subcloned human
esophageal squamous cell carcinoma cell line with low thrombomodulin
expression showed increased invasiveness compared with a high
thrombomodulin-expressing clone – thrombomodulin as a possible
candidate for an adhesion molecule of squamous cell carcinoma. Cancer
Lett 127: 195–201
Mizutani H, Ohyanagi S, Hayashi T, Groves RW, Suzuki K, Shimizu M
(1996) Functional thrombomodulin expression on epithelial skin
tumours as a differentiation marker for suprabasal keratinocytes. Br J
Dermatol 135: 187–193
Ogawa H, Yonezawa S, Maruyama I, Matsushita Y, Tezuka Y, Toyoyama H,
Yanagi M, Matsumoto H, Nishijima H, Shimotakahara T, Aikou T, Sato E
(2000) Expression of thrombomodulin in squamous cell carcinoma of the
lung: its relationship to lymph node metastasis and prognosis of the
patients. Cancer Lett 149: 95–103
Ohji T, Urano H, Shirahata A, Yamagishi M, Higashi K, Gotoh S, Karasaki Y
(1995) Transforming growth factor beta 1 and beta 2 induce down-
modulation of thrombomodulin in human umbilical vein endothelial
cells. Thromb Haemost 73: 812–818
Ordonez NG (1997) Value of thrombomodulin immunostaining in the
diagnosis of transitional cell carcinoma: a comparative study with
carcinoembryonic antigen. Histopathology 31: 517–524
Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U, Lin
P, Fink LM, Hauer-Jensen M (2003) Statins increase thrombomodulin
expression and function in human endothelial cells by a nitric oxide-
dependent mechanism and counteract tumor necrosis factor alpha-
induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 14:
575–585
Tabata M, Sugihara K, Yonezawa S, Yamashita S, Maruyama I (1997) An
immunohistochemical study of thrombomodulin in oral squamous cell
carcinoma and its association with invasive and metastatic potential.
J Oral Pathol Med 26: 258–264
Tabata M, Yonezawa S, Sugihara K, Yamashita S, Maruyama I (1995)
The use of thrombomodulin to study epithelial cell differentiation
in neoplastic and non-neoplastic oral lesions. J Oral Pathol Med 24:
443–449
Takebayashi Y, Yamada K, Maruyama I, Fujii R, Akiyama S, Aikou T (1995)
The expression of thymidine phosphorylase and thrombomodulin in
human colorectal carcinomas. Cancer Lett 92: 1–7
Tezuka Y, Yonezawa S, Maruyama I, Matsushita Y, Shimizu T, Obama H,
Sagara M, Shirao K, Kusano C, Natsugoe S (1995) Expression of
thrombomodulin in esophageal squamous cell carcinoma and its
relationship to lymph node metastasis. Cancer Res 55: 4196–4200
Waugh JM, Yuksel E, Li J, Kuo MD, Kattash M, Saxena R, Geske R, Thung
SN, Shenaq SM, Woo SL (1999) Local overexpression of thrombo-
modulin for in vivo prevention of arterial thrombosis in a rabbit model.
Circ Res 84: 84–92
Weiler H, Isermann BH (2003) Thrombomodulin. J Thromb Haemost 1:
1515–1524
Weiler H, Lindner V, Kerlin B, Isermann BH, Hendrickson SB, Cooley BC,
Meh DA, Mosesson MW, Shworak NW, Post MJ, Conway EM, Ulfman
Thrombomodulin and colorectal carcinoma
AM Hanly et al
1324
British Journal of Cancer (2006) 94(9), 1320–1325 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sLH, von Andrian UH, Weitz JI (2001) Characterization of a mouse
model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol 21:
1531–1537
Wilhelm S, Schmitt M, Parkinson J, Kuhn W, Graeff H, Wilhelm OG (1998)
Thrombomodulin, a receptor for the serine protease thrombin, is
decreased in primary tumors and metastases but increased in ascitic
fluids of patients with advanced ovarian cancer FIGO IIIc. Int J Oncol 13:
645–651
Yonezawa S, Maruyama I, Sakae K, Igata A, Majerus PW, Sato E (1987)
Thrombomodulin as a marker for vascular tumors. Comparative study
with factor VIII and Ulex europaeus I lectin. Am J Clin Pathol 88: 405–411
Zhang Y, Weiler-Guettler H, Chen J, Wilhelm O, Deng Y, Qiu F, Nakagawa
K, Klevesath M, Wilhelm S, Bohrer H, Nakagawa M, Graeff H, Martin E,
Stern DM, Rosenberg RD, Ziegler R, Nawroth PP (1998) Thrombo-
modulin modulates growth of tumor cells independent of its anti-
coagulant activity. J Clin Invest 101: 1301–1309
Thrombomodulin and colorectal carcinoma
AM Hanly et al
1325
British Journal of Cancer (2006) 94(9), 1320–1325 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s